Navigation Links
Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
Date:8/29/2007

BOCA RATON, Fla., Aug. 29 /PRNewswire/ -- Dawson James Securities, a full- service investment firm serving the healthcare and biotechnology industry, initiated research coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy rating and a 12-18 month price target of $6.00. John M. Putnam, Sr. VP-Medical Devices, issued the report.

The report describes CryoCor's recently FDA-approved cryoablation system for atrial flutter and their current pivotal trial for atrial fibrillation. Mr. Putnam states "With the FDA's approval of CryoCor's cryoablation system for the treatment of atrial flutter, and the strong prospect of an approval for treating the much larger indication of atrial fibrillation in 2008, we believe the company is on the verge of meaningful revenue generation."

A copy of the report may be obtained by contacting Dawson James Securities at 561-391-5555.

About Dawson James Securities:

Dawson James Securities is a full service investment firm with deep expertise in healthcare and biotechnology and having a staff of over 50 investment professionals providing institutional research, investment banking and high net worth services to our clients. More information is available at http://www.DawsonJames.com

Disclosures:

Dawson James has not acted as an investment banker for the company mentioned in this report in the past, although Dawson James may have sought in the past, or may actively seek in the future, compensation for investment banking services. Dawson James and/or its directors and employees may own securities in the companies and may increase or decrease holdings in the future.

The analyst certifies that 1) all of the views expressed accurately reflect his personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst; 3) the analyst responsible for preparing this research report receives compensation based upon various factors, including total revenues of Dawson James and its affiliates, a portion of which is generated by investment banking activities and 4) the analyst and/or members of their immediate family do not own stock in the companies mentioned.

Contact:

Dawson James Securities

John M. Putnam, 561-208-2950

Fax: 561-391-5757

Dawson James Securities is a member of the National Association of Securities Dealers, CRD number 130645.


'/>"/>
SOURCE Dawson James Securities
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. State puts up $1 million for James Thomsons new stem cell startup
3. OpGen adds Thomas Pyle and James Ogle to board of directors
4. UW stem-cell team led by James Thomson gets $1.25M private grant
5. James Thomson plans to stay in Madison to study genesis of stem cells
6. Early Stage, Step 9: Raising capital in the securities landscape
7. Securities compliance is part of raising capital
8. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
9. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
10. Control Your siRNA Research
11. Getting Started with MicroRNA Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
Breaking Biology Technology:
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):